Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein

Frontiers in Behavioral Neuroscience

Volumn 9, Issue , 2015, Pages

  Bentea, Eduard ^a   Van der Perren, Anke ^b   Van Liefferinge, Joeri ^a   El Arfani, Anissa ^a   Albertini, Giulia ^a   Demuyser, Thomas ^a   Merckx, Ellen ^a   Michotte, Yvette ^a   Smolders, Ilse ^a   Baekelandt, Veerle ^b   Massie, Ann ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Lactacystin; Mouse model; Non motor behavior; Parkinson s disease; Proteasome; synuclein

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; PROTEASOME; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CELL LOSS; COGNITIVE DEFECT; CONSTRUCT VALIDITY; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; FACE VALIDITY; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SOMATOSENSORY DISORDER; SUBSTANTIA NIGRA;

EID: 84939560212     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2015.00068     Document Type: Article

References (106)

1. Anderson, J. P., Walker, D. E., Goldstein, J. M., De Laat, R., Banducci, K., Caccavello, R. J., et al. (2006). Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739-29752. doi: 10.1074/jbc.M600933200
2. Borlongan, C. V., and Sanberg, P. R. (1995). Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J. Neurosci. 15, 5372-5378.
3. Bouet, V., Boulouard, M., Toutain, J., Divoux, D., Bernaudin, M., Schumann-Bard, P., et al. (2009). The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat. Protoc. 4, 1560-1564. doi: 10.1038/nprot.2009.125
4. Brichta, L., and Greengard, P. (2014). Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update. Front. Neuroanat. 8:152. doi: 10.3389/fnana.2014.00152
5. Bukhatwa, S., Zeng, B. Y., Rose, S., and Jenner, P. (2010). A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Brain. Res. 1326, 174-183. doi: 10.1016/j.brainres.2010.02.045
6. Cenci, M. A., Whishaw, I. Q., and Schallert, T. (2002). Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci. 3, 574-579. doi: 10.1038/nrn877
7. Chaudhuri, K. R., and Schapira, A. H. (2009). Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8, 464-474. doi: 10.1016/S1474-4422(09)70068-7
8. Comella, C. L., and Goetz, C. G. (1994). Akathisia in Parkinson’s disease. Mov. Disord. 9, 545-549. doi: 10.1002/mds.870090507
9. Conte, A., Khan, N., Defazio, G., Rothwell, J. C., and Berardelli, A. (2013). Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat. Rev. Neurol. 9, 687-697. doi: 10.1038/nrneurol.2013.224
10. Cools, R., Barker, R. A., Sahakian, B. J., and Robbins, T. W. (2001). Mechanisms of cognitive set flexibility in Parkinson’s disease. Brain 124, 2503-2512. doi: 10.1093/brain/124.12.2503
11. Costa, A., Peppe, A., Mazzu, I., Longarzo, M., Caltagirone, C., and Carlesimo, G. A. (2014). Dopamine treatment and cognitive functioning in individuals with Parkinson’s disease: the "cognitive flexibility" hypothesis seems to work.Behav. Neurol. 2014:260896. doi: 10.1155/2014/260896
12. Darvas, M., Henschen, C. W., and Palmiter, R. D. (2014). Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson’s disease. Neurobiol. Dis. 65, 112-123. doi: 10.1016/j.nbd.2014.01.017
13. Dawson, T., Mandir, A., and Lee, M. (2002). Animal models of PD: pieces of the same puzzle? Neuron 35, 219-222. doi: 10.1016/S0896-6273(02)00780-8
14. Deacon, R. M. (2006). Assessing nest building in mice. Nat. Protoc. 1, 1117-1119. doi: 10.1038/nprot.2006.170
15. Dexter, D. T., and Jenner, P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free. Radic. Biol. Med. 62, 132-144. doi: 10.1016/j.freeradbiomed.2013.01.018
16. Dick, L. R., Cruikshank, A. A., Destree, A. T., Grenier, L., McCormack, T. A., Melandri, F. D., et al. (1997). Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272, 182-188. doi: 10.1074/jbc.272.1.182
17. Dick, L. R., Cruikshank, A. A., Grenier, L., Melandri, F. D., Nunes, S. L., and Stein, R. L. (1996). Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J. Biol. Chem. 271, 7273-7276. doi: 10.1074/jbc.271.13.7273
18. Drui, G., Carnicella, S., Carcenac, C., Favier, M., Bertrand, A., Boulet, S., et al. (2014). Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease. Mol. Psychiatry 19, 358-367. doi: 10.1038/mp.2013.3
19. Dunnett, S. B., and Lelos, M. (2010). Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson’s disease. Prog. Brain. Res. 184, 35-51. doi: 10.1016/S0079-6123(10)84003-8
20. Duty, S., and Jenner, P. (2011). Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 164, 1357-1391. doi: 10.1111/j.1476-5381.2011.01426.x
21. Ebersbach, G., Hattig, H., Schelosky, L., Wissel, J., and Poewe, W. (1994). Perseverative motor behaviour in Parkinson’s disease. Neuropsychologia 32, 799-804. doi: 10.1016/0028-3932(94)90018-3
22. Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B. T., et al. (2011). Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 31, 14508-14520. doi: 10.1523/JNEUROSCI.1560-11.2011
23. Ebrahimi-Fakhari, D., Wahlster, L., and McLean, P. J. (2012). Protein degradation pathways in Parkinson’s disease: curse or blessing. Acta. Neuropathol. 124, 153-172. doi: 10.1007/s00401-012-1004-6
24. Fenteany, G., and Schreiber, S. L. (1998). Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273, 8545-8548. doi: 10.1074/jbc.273.15.8545
25. Fornaguera, J., Schwarting, R. K., Boix, F., and Huston, J. P. (1993). Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson’s model. Synapse 13, 179-185. doi: 10.1002/syn.890130209
26. Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Busceti, C. L., et al. (2003). Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci. 23, 8955-8966.
27. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., et al. (2002). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell. Biol. 4, 160-164. doi: 10.1038/ncb748
28. Furukawa, Y., Vigouroux, S., Wong, H., Guttman, M., Rajput, A. H., Ang, L., et al. (2002). Brain proteasomal function in sporadic Parkinson’s disease and related disorders. Ann. Neurol. 51, 779-782. doi: 10.1002/ana.10207
29. Gerlai, R. (2002). Phenomics: fiction or the future? Trends. Neurosci. 25, 506-509. doi: 10.1016/S0166-2236(02)02250-6
30. Gjerstad, M. D., Tysnes, O. B., and Larsen, J. P. (2011). Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 77, 1941-1946. doi: 10.1212/WNL.0b013e31823a0cc8
31. Glajch, K. E., Fleming, S. M., Surmeier, D. J., and Osten, P. (2012). Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson’s disease. Behav. Brain. Res. 230, 309-316. doi: 10.1016/j.bbr.2011.12.007
32. Goncalves, S., and Outeiro, T. F. (2013). Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Mol. Neurobiol. 47, 1081-1092. doi: 10.1007/s12035-013-8406-x
33. Grunblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., et al. (2004). Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural. Transm. 111, 1543-1573. doi: 10.1007/s00702-004-0212-1
34. Healy-Stoffel, M., Omar Ahmad, S., Stanford, J. A., and Levant, B. (2014). Differential effects of intrastriatal 6-hydroxydopamine on cell number and morphology in midbrain dopaminergic subregions of the rat. Brain. Res. 1574, 113-119. doi: 10.1016/j.brainres.2014.05.045
35. Hinnell, C., Hurt, C. S., Landau, S., Brown, R. G., and Samuel, M. (2012). Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov. Disord. 27, 236-241. doi: 10.1002/mds.23961
36. Hoglinger, G. U., Carrard, G., Michel, P. P., Medja, F., Lombes, A., Ruberg, M., et al. (2003). Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J. Neurochem. 86, 1297-1307. doi: 10.1046/j.1471-4159.2003.01952.x
37. Huston, J. P., Steiner, H., Weiler, H. T., Morgan, S., and Schwarting, R. K. (1990). The basal ganglia-orofacial system: studies on neurobehavioral plasticity and sensory-motor tuning. Neurosci. Biobehav. Rev. 14, 433-446. doi: 10.1016/S0149-7634(05)80066-1
38. Iancu, R., Mohapel, P., Brundin, P., and Paul, G. (2005). Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav. Brain. Res. 162, 1-10. doi: 10.1016/j.bbr.2005.02.023
39. Inden, M., Kondo, J., Kitamura, Y., Takata, K., Nishimura, K., Taniguchi, T., et al. (2005). Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats. J. Pharmacol. Sci. 97, 203-211. doi: 10.1254/jphs.FP0040525
40. Jain, S., and Goldstein, D. S. (2012). What ARE Parkinson disease? Non-motor features transform conception of the shaking palsy. Neurobiol. Dis. 46, 505-507. doi: 10.1016/j.nbd.2012.04.013
41. Jenner, P. (2008). Functional models of Parkinson’s disease: a valuable tool in the development of novel therapies.Ann. Neurol. 64(Suppl. 2), S16-S29. doi: 10.1002/ana.21489
42. Jeon, B. S., Jackson-Lewis, V., and Burke, R. E. (1995). 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 4, 131-137. doi: 10.1006/neur.1995.0016
43. Kieburtz, K., and Olanow, C. W. (2007). Translational experimental therapeutics: the translation of laboratory-based discovery into disease-related therapy. Mt. Sinai J. Med. 74, 7-14. doi: 10.1002/msj.20006
44. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., and Altman, D. G. (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8:e1000412. doi: 10.1371/journal.pbio.1000412
45. Konieczny, J., Czarnecka, A., Lenda, T., Kaminska, K., and Lorenc-Koci, E. (2014). Chronic l-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra. Behav. Brain. Res. 261, 79-88. doi: 10.1016/j.bbr.2013.12.019
46. Koob, G. F., Stinus, L., and Le Moal, M. (1981). Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behav. Brain. Res. 3, 341-359. doi: 10.1016/0166-4328(81)90004-8
47. Lang, A. E., and Johnson, K. (1987). Akathisia in idiopathic Parkinson’s disease. Neurology 37, 477-481. doi: 10.1212/WNL.37.3.477
48. Lauwers, E., Beque, D., Van Laere, K., Nuyts, J., Bormans, G., Mortelmans, L., et al. (2007). Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol. Aging 28, 248-257. doi: 10.1016/j.neurobiolaging.2005.12.005
49. Le, W. (2014). Role of iron in UPS impairment model of Parkinson’s disease. Parkinsonism. Relat. Disord. 20(Suppl. 1), S158-S161. doi: 10.1016/S1353-8020(13)70038-5
50. Lees, G. J., Kydd, R. R., and Wright, J. J. (1985). Relationship between sensorimotor neglect and the specificity, degree and locus of mesotelencephalic dopaminergic cell loss following 6-hydroxydopamine.Psychopharmacology 85, 115-122. doi: 10.1007/BF00427334
51. Li, X., Yang, D., Li, L., Peng, C., Chen, S., and Le, W. (2007). Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem. Int. 50, 959-965. doi: 10.1016/j.neuint.2007.04.014
52. Li, X. P., Xie, W. J., Zhang, Z., Kansara, S., Jankovic, J., and Le, W. D. (2012). A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals 20, 223-236. doi: 10.1159/000332954
53. Lim, K. L. (2007). Ubiquitin-proteasome system dysfunction in Parkinson’s disease: current evidence and controversies. Expert. Rev. Proteomics. 4, 769-781. doi: 10.1586/14789450.4.6.769
54. Lim, K. L., and Zhang, C. W. (2013). Molecular events underlying Parkinson’s disease-an interwoven tapestry.Front. Neurol. 4:33. doi: 10.3389/fneur.2013.00033
55. Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., et al. (2010). Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J. Biol. Chem. 285, 40732-40744. doi: 10.1074/jbc.M110.141952
56. Mackey, S., Jing, Y., Flores, J., Dinelle, K., and Doudet, D. J. (2013). Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry.Exp. Neurol. 247, 19-24. doi: 10.1016/j.expneurol.2013.03.021
57. Martinez-Martin, P. (2011). The importance of non-motor disturbances to quality of life in Parkinson’s disease. J. Neurol. Sci. 310, 12-16. doi: 10.1016/j.jns.2011.05.006
58. Martinez-Martin, P., and Damian, J. (2010). Parkinson disease: depression and anxiety in Parkinson disease. Nat. Rev. Neurol. 6, 243-245. doi: 10.1038/nrneurol.2010.49
59. Massano, J., and Bhatia, K. P. (2012). Clinical approach to Parkinson’s disease: features, diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2:a008870. doi: 10.1101/cshperspect.a008870
60. Massie, A., Schallier, A., Kim, S. W., Fernando, R., Kobayashi, S., Beck, H., et al. (2011). Dopaminergic neurons of system x(c)(-)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB J. 25, 1359-1369. doi: 10.1096/fj.10-177212
61. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2003). Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol. 179, 38-46. doi: 10.1006/exnr.2002.8050
62. McNaught, K. S., Belizaire, R., Jenner, P., Olanow, C. W., and Isacson, O. (2002a). Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci. Lett. 326, 155-158. doi: 10.1016/S0304-3940(02)00296-3
63. McNaught, K. S., Bjorklund, L. M., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2002b). Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13, 1437-1441. doi: 10.1097/00001756-200208070-00018
64. McNaught, K. S., and Jenner, P. (2001). Proteasomal function is impaired in substantia nigra in Parkinson’s disease.Neurosci. Lett. 297, 191-194. doi: 10.1016/S0304-3940(00)01701-8
65. McNaught, K. S., and Olanow, C. W. (2006). Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol. Aging 27, 530-545. doi: 10.1016/j.neurobiolaging.2005.08.012
66. McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., and Jenner, P. (2001). Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat. Rev. Neurosci. 2, 589-594. doi: 10.1038/35086067
67. McRitchie, D. A., Cartwright, H. R., and Halliday, G. M. (1997). Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson’s disease. Exp. Neurol. 144, 202-213. doi: 10.1006/exnr.1997.6418
68. Miwa, H., Kubo, T., Suzuki, A., Nishi, K., and Kondo, T. (2005). Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci. Lett. 380, 93-98. doi: 10.1016/j.neulet.2005.01.024
69. Mytilineou, C., McNaught, K. S., Shashidharan, P., Yabut, J., Baptiste, R. J., Parnandi, A., et al. (2004). Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J. Neural. Transm. 111, 1237-1251. doi: 10.1007/s00702-004-0167-2
70. Nair, V. D., McNaught, K. S., Gonzalez-Maeso, J., Sealfon, S. C., and Olanow, C. W. (2006). p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J. Biol. Chem. 281, 39550-39560. doi: 10.1074/jbc.M603950200
71. Naismith, S. L., Shine, J. M., and Lewis, S. J. (2010). The specific contributions of set-shifting to freezing of gait in Parkinson’s disease. Mov. Disord. 25, 1000-1004. doi: 10.1002/mds.23005
72. Olanow, C. W., and McNaught, K. S. (2006). Ubiquitin-proteasome system and Parkinson’s disease. Mov. Disord. 21, 1806-1823. doi: 10.1002/mds.21013
73. Oliveras-Salva, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D’Hooge, R., et al. (2013). rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol. Neurodegener. 8:44. doi: 10.1186/1750-1326-8-44
74. Pagonabarraga, J., and Kulisevsky, J. (2012). Cognitive impairment and dementia in Parkinson’s disease.Neurobiol. Dis. 46, 590-596. doi: 10.1016/j.nbd.2012.03.029
75. Patel, N., Jankovic, J., and Hallett, M. (2014). Sensory aspects of movement disorders. Lancet Neurol. 13, 100-112. doi: 10.1016/S1474-4422(13)70213-8
76. Paxinos, G., and Franklin, K. B. J. (2007). The Mouse Brain in Stereotaxic Coordinates, 3rd Edn. San Diego, CA: Academic Press.
77. Perez-Alvarez, S., Solesio, M. E., Manzanares, J., Jordan, J., and Galindo, M. F. (2009). Lactacystin requires reactive oxygen species and Bax redistribution to induce mitochondria-mediated cell death. Br. J. Pharmacol. 158, 1121-1130. doi: 10.1111/j.1476-5381.2009.00388.x
78. Petrucelli, L., O’Farrell, C., Lockhart, P. J., Baptista, M., Kehoe, K., Vink, L., et al. (2002). Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36, 1007-1019. doi: 10.1016/S0896-6273(02)01125-X
79. Pienaar, I. S., Harrison, I. F., Elson, J. L., Bury, A., Woll, P., Simon, A. K., et al. (2015). An animal model mimicking pedunculopontine nucleus cholinergic degeneration in Parkinson’s disease. Brain. Struct. Funct. 220, 479-500. doi: 10.1007/s00429-013-0669-5
80. Pifl, C., and Hornykiewicz, O. (2006). Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem. Int. 49, 519-524. doi: 10.1016/j.neuint.2006.03.013
81. Pioli, E. Y., Meissner, W., Sohr, R., Gross, C. E., Bezard, E., and Bioulac, B. H. (2008). Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience 153, 1213-1224. doi: 10.1016/j.neuroscience.2008.01.084
82. Pogorelov, V. M., Lanthorn, T. H., and Savelieva, K. V. (2007). Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice. J. Neurosci. Methods 162, 222-228. doi: 10.1016/j.jneumeth.2007.01.015
83. Reaney, S. H., Johnston, L. C., Langston, W. J., and Di Monte, D. A. (2006). Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp. Neurol. 202, 434-440. doi: 10.1016/j.expneurol.2006.07.010
84. Rideout, H. J., Lang-Rollin, I. C., Savalle, M., and Stefanis, L. (2005). Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem. 93, 1304-1313. doi: 10.1111/j.1471-4159.2005.03124.x
85. Roghani, M., Behzadi, G., and Baluchnejadmojarad, T. (2002). Efficacy of elevated body swing test in the early model of Parkinson’s disease in rat. Physiol. Behav. 76, 507-510. doi: 10.1016/S0031-9384(02)00753-9
86. Sako, W., Murakami, N., Izumi, Y., and Kaji, R. (2014). MRI can detect nigral volume loss in patients with Parkinson’s disease: evidence from a meta-analysis. J. Parkinsons Dis. 4, 405-411. doi: 10.3233/JPD-130332
87. Sato, H., Arawaka, S., Hara, S., Fukushima, S., Koga, K., Koyama, S., et al. (2011). Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease. J. Neurosci. 31, 16884-16894. doi: 10.1523/JNEUROSCI.3967-11.2011
88. Sawada, H., Kohno, R., Kihara, T., Izumi, Y., Sakka, N., Ibi, M., et al. (2004). Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 279, 10710-10719. doi: 10.1074/jbc.M308434200
89. Schapira, A. H. (2009). Neurobiology and treatment of Parkinson’s disease. Trends Pharmacol. Sci. 30, 41-47. doi: 10.1016/j.tips.2008.10.005
90. Sedelis, M., Schwarting, R. K., and Huston, J. P. (2001). Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav. Brain Res. 125, 109-125. doi: 10.1016/S0166-4328(01)00309-6
91. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature 388, 839-840. doi: 10.1038/42166
92. Steiner, H., Bonatz, A. E., Huston, J. P., and Schwarting, R. (1988). Lateralized wall-facing versus turning as measures of behavioral asymmetries and recovery of function after injection of 6-hydroxydopamine into the substantia nigra. Exp. Neurol. 99, 556-566. doi: 10.1016/0014-4886(88)90172-0
93. Subramaniam, M., Kern, B., Vogel, S., Klose, V., Schneider, G., and Roeper, J. (2014). Selective increase of in vivofiring frequencies in DA SN neurons after proteasome inhibition in the ventral midbrain. Eur. J. Neurosci. 40, 2898-2909. doi: 10.1111/ejn.12660
94. Tanaka, M., Kim, Y. M., Lee, G., Junn, E., Iwatsubo, T., and Mouradian, M. M. (2004). Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625-4631. doi: 10.1074/jbc.M310994200
95. Taylor, T. N., Greene, J. G., and Miller, G. W. (2010). Behavioral phenotyping of mouse models of Parkinson’s disease. Behav. Brain Res. 211, 1-10. doi: 10.1016/j.bbr.2010.03.004
96. Tenreiro, S., Eckermann, K., and Outeiro, T. F. (2014). Protein phosphorylation in neurodegeneration: friend or foe? Front. Mol. Neurosci. 7:42. doi: 10.3389/fnmol.2014.00042
97. Tofaris, G. K., Layfield, R., and Spillantini, M. G. (2001). alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509, 22-26. doi: 10.1016/S0014-5793(01)03115-5
98. Tofaris, G. K., Razzaq, A., Ghetti, B., Lilley, K. S., and Spillantini, M. G. (2003). Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 44405-44411. doi: 10.1074/jbc.M308041200
99. Tydlacka, S., Wang, C. E., Wang, X., Li, S., and Li, X. J. (2008). Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J. Neurosci. 28, 13285-13295. doi: 10.1523/JNEUROSCI.4393-08.2008
100. Van der Perren, A., Toelen, J., Casteels, C., Macchi, F., Van Rompuy, A. S., Sarre, S., et al. (2015). Longitudinal follow-up and characterization of a robust rat model for Parkinson’s disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiol. Aging. 36, 1543-1558. doi: 10.1016/j.neurobiolaging.2014.11.015
101. Vernon, A. C., Crum, W. R., Johansson, S. M., and Modo, M. (2011). Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson’s disease. PLoS ONE 6:e17269. doi: 10.1371/journal.pone.0017269
102. Vernon, A. C., Johansson, S. M., and Modo, M. M. (2010). Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson’s disease. BMC Neurosci. 11:1. doi: 10.1186/1471-2202-11-1
103. Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M., et al. (2007). Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J. Neurosci. Res. 85, 1819-1825. doi: 10.1002/jnr.21310
104. Wang, H., Liang, X., Wang, X., Luo, D., and Jia, J. (2013). Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated mice. PLoS ONE 8:e64403. doi: 10.1371/journal.pone.0064403
105. Winn, P. (2006). How best to consider the structure and function of the pedunculopontine tegmental nucleus: evidence from animal studies. J. Neurol. Sci. 248, 234-250. doi: 10.1016/j.jns.2006.05.036
106. Xie, W., Li, X., Li, C., Zhu, W., Jankovic, J., and Le, W. (2010). Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease. J. Neurochem. 115, 188-199. doi: 10.1111/j.1471-4159.2010.06914.x